41 results about "Treatment resistant" patented technology

The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.

The invention is directed to a method of monitoring or detecting treatment-resistant clones in a patient being treated for a lymphoid or myeloid neoplasm from which patient-specific correlating clonotypes have been identified. In some embodiments, such method includes the steps of obtaining a sample from the patient comprising T-cells and / or B-cells; amplifying molecules of nucleic acid from the T-cells and / or B-cells of the sample, the molecules of nucleic acid comprising recombined DNA sequences from T-cell receptor genes or immunoglobulin genes; sequencing the amplified molecules of nucleic acid to form a clonotype profile; determining from the clonotype profile a level of each correlating clonotype and clonotypes clonally evolved therefrom; and correlating a presence of a treatment-resistant clone of the neoplasm with a change in relative levels of the correlating clonotypes and clonotypes clonally evolved therefrom. In part, the invention permits one to distinguish between cases where treatment is effective but insufficiently intense and cases where a cancer clone arises that is resistant to a current treatment approach.

A high-temperature annealing treatment resistant single-component chromium-free aqueous silicon steel sheet insulated masking liquid is characterized in that the main ingredients include organic resin, inorganic water dispersion liquid, curing agent and other additives. The weight ratio of the components is as follows: 100 parts of the organic resin, 100-400 parts of inorganic matter, 5-30 parts of the curing agent, 1-20 parts of additive surface active agent and the rest of water, and the solid content of the masking liquid is 30-50 percent. The masking liquid does not contain toxic organic solvent and chromate, has excellent performances of coating appearance, adhesion, salt spray resistance, insulativity and the like, and can still keep good insulativity after going through high-temperature stress annealing process. After a high-temperature annealing experiment (nitrogen atmosphere, 750 DEG C / 2h), the interface resistance retention value is more than 70 percent. The curing speed of the masking liquid is fast, the curing is thorough, and the surface of the membranous layer does not turn sticky for a long time of placement after curing. The masking liquid is in the form of single component, has convenient use and can be stored for long time.

The invention provides a normalized and annealed treatment resistant refractory steel electrode, comprising 40-60 portions of marble, 18-2. portions of fluorite, 5-7 portions of quartz, 11-13 portions of ferrotitanium, 3-7 portions of ferrosilicon, 1.5-3 portions of medium carbon ferromanganese, 2.5-3.5 portions of ferromolybdenum, 4.5-7.5 portions of high carbon ferrochrome and 0.5-1.5 portions of soda, and after being mixed uniformly, 16-23 portions of sodium silicate is added. The butt core H08A is extruded and formed into semi-finished product through an oil press typed electrode extruder, and the finished product is made after being dried with low temperature of 80 DEG C and high temperature of 400 DEG C. Before welding, the electrode should be dried for one hour under the temperature of 350-400 DEG C. The direct current is directly connected reversely while welding with the current of 150-180A, arc voltage of 22-28V, welding speed of 100-200mm / min and interpass temperature of 160-220 DEG C. The welding seam after being processed with heat treatment has excellent high temperature usability, which can satisfy the requirements that Rp0.2 is equal to or more than 275 MPa and Rm is equal to 450-685 MPa.

The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by down-regulating the expression of either protein.

An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.

The present invention relates to the use of anatiomeric pure escitalopram and / or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment resistant" patients.

Topical formulations for prophylaxis or elimination of susceptible and treatment resistant head lice wherein the formulation is an aqueous dispersion of an oil phase containing an effective amount of an active ingredient component combining at least one compound that binds to glutamate-gated chloride ion channels and at least one compound that binds to gamma-amino butyric acid (GABA) receptors, dissolved in at least one water-soluble or water-miscible surface active agent with one or more suspending agents and one or more non-ionic surfactants. Also disclosed are methods of using the topical formulations to treat or prevent an infestation of either a susceptible or treatment resistant strain of head lice in a human patient.

The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a benzofuran, such as 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide (HCV-796), and at least one additional anti-Hepatitis C agent, e.g., a ribavirin product or an immunomodulator, such as an interferon product. Additionally, the invention relates to methods of monitoring the course of treatment of a Hepatitis C viral infection, methods of monitoring and prognosing a Hepatitis C viral infection, and methods of identifying an individual with a decreased likelihood of responding to an anti-Hepatitis C viral therapy. These methods use the sequence and / or structure of the Hepatitis C RNA-dependent RNA polymerase NS5B to identify the emergence of a treatment-resistant Hepatitis C viral infection, particularly a benzofuran (e.g., HCV-796) treatment-resistant Hepatitis C viral infection.

This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

The invention provides a high temperature heat treatment resistant DM code label and a manufacturing method thereof. The manufacturing method comprises the following steps: coating a uniform, compact and tightly-bound golden yellow ZrN coating on the surface of TC4 titanium alloy as a label, controlling the thickness of the ZrN coating in a range of 1 um to 10 um, and engraving a DM code on the ZrN coating with a fiber laser through a back engraving technique so as to form the high temperature heat treatment resistant DM code label. The DM code is in accord with the DM code in a part, then the label is placed on the part, a heat treatment is carried out on the label and the part, and the DM code is transferred to the part after the heat treatment. The method that the matrix surface is directly engraved in the prior art is changed by the manufacturing method provided by the invention; the manufacturing method first deposits a high temperature resistant film on a matrix surface through a physical method, then carries out a laser labeling method; the high temperature heat treatment resistant performance of the DM code label formed by the manufacturing method is largely improved; besides the manufacturing method is suitable for being used under a high temperature environment, the coating tightly binds with the matrix, the parts processed by the manufacturing method are suitable for being subjected to a stress relief treatment, an aging treatment and a tempering treatment.

Methods and reports for presenting genetic information that is patient-specific and relevant to treatment of neuropsychiatric disorders, including treatment resistant depression. The methods and reports described include genotype information for each of six specific genetic loci and allow patient-specific therapy for the effective treatment of treatment resistant disorders (TRD).

The present invention relates to novel N-substituted azetidine derivatives < of the formula (I); wherein SERMF is a Selective Estrogen Receptor Modilator fragment; X is no atom, O, S, CH2, carbonyl, N—R5; R1 is H, (C1-8)alkyl, (C3-8)cycloalkyl, (C3-6)heterocycloalkyl, (C2-6)alkenyl, (C2-6)alkynyl, (C1-4)alkylcarbonyl, (C1-4)alkoxy(C2-4)alkyl, (C3-6)cycloalkyl(C1-3)-alkyl, (C3-6)heterocycloalkyl(C1-3)alkyl, each independently optionally substituted with one or more halogen, nitrile, hydroxyl or (C1-2)alkyl; R5 is H, (C1-3)alkyl, optionally substituted with one or more fluorine; R17, R18 and R19 are independently of each other H, fluorine, nitrile or (C1-3)-alkyl, optionally substituted with one or more fluorine; or a prodrug, isotopically-labelled derivative or pharmaceutically acceptable salt thereof, > to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the prevention or treatment of ovulatory dysfunction, uterine cancer, endometrium cancer, ovarian cancer, endometriosis, osteoporosis, prostate cancer, benign prostatic hypertrophy, and breast cancer, in particular ER-positive breast cancer, more in particular ER-positive, hormone treatment-resistant breast cancer. Said N-substituted azetidine derivatives have estrogen receptor alpha (ERa) antagonistic and—in certain embodiments—selective estrogen receptor downregulating (SERD) activity in ER-positive breast cancer cells.

Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I):including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for the treatment of various diseases including, for example, neurological disorders such as amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, and cancers such as melanoma, breast cancer, brain cancer, and prostate cancer.

The invention relates to a cigarette breaking device, and belongs to the field of waste cigarette recycling equipment in tobacco industry. The cigarette breaking device comprises a movable breaking structure, a fixed breaking structure and two auxiliary support structures, wherein the movable breaking structure is arranged on the two auxiliary support structures through bearings; the fixed breaking structure is fixedly arranged on the two auxiliary support structures; the fixed breaking structure and the movable breaking structure are arranged in parallel; the fixed breaking structure is positioned at the back side of the movable breaking structure. The cigarette breaking device has the advantages that the waste cigarette is physically broken and pretreated by the movable breaking structure on the auxiliary support structures under the cooperation function of the fixed breaking structure; because the length of the broken waste cigarette is reduced, the treatment-resistant property of the subsequent waste cigarette treatment machine is reduced, the cigarette shred is easy to separate from the cigarette paper, and the waste of cigarette shred in the cigarette paper is reduced; the working is reliable, and the working efficiency is high.

Methods and apparatus for classifying or predicting the classes for samples based on gene expression are described. Also described are methods and apparatus for ascertaining or discovering new, previously unknown classes based on gene expression. Methods, computer systems and apparatus for classifying or predicting whether a sample is treatment sensitive (e.g., chemosensitive) or treatment resistant (e.g., chemoresistant) are also provided. Classification occurs based on analysis of gene expression data from samples that have been subjected to one or more compounds.

[Problem to be Solved] It is an object of the present invention to provide a preventive or therapeutic composition for a therapy-resistant cancer having therapy-resistant cancer cells.[Solution] A preventive or therapeutic composition for a therapy-resistant cancer having therapy-resistant cancer cells, which is for use in photodynamic therapy, wherein the composition comprises ALAs.

This invention relates generally to animal models of anxiety and depression. Specifically, this invention relates to an in vivo high utility, high-throughput model for screening anxiolytic / antidepressant drugs in fowl chicks with stress vulnerability. This new animal model utilizes an inexpensive avian model, measures spontaneous behaviors in very young animals, and is capable of detecting and / or differentiating a compound's anxiolytic and / or antidepressant effects. This new animal model is especially useful in detecting and / or differentiating a compound's anxiolytic and / or antidepressant effects in treatment-resistant subjects. Animal costs are less than 10% of rodent costs and the assay can be run in a high-throughput mode.

Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided.Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided.

The present invention provides methods and compositions for enhancing efficacy of anti-hormone treatment, or for preventing cancer relapse or progression following treatment. The invention also provides methods for re-sensitizing or sensitizing treatment resistant cancer cells or patients with treatment-refractory cancer cells to continuing or starting anti-hormone treatment. Further provided in the invention are methods for prognosis or diagnosis of anti-hormone treatment effect or likelihood of cancer relapse or metastasis following anti-hormone treatment.

This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia / asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition / apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition / apathy; ii) anhedonia / asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.

This invention relates to methods and compositions that are useful for the treatment of various cancers, including primary and secondary liver cancers. The cancers can be metastatic cancer in the liver, or cancers that have metastasized from liver. The invention relates to, in part, uses of quinacrine in the manufacture of a medicament for treatment-resistant liver cancer.